ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)
China · Delayed Price · Currency is CNY 38.77
+3.26 (9.18%)
At close: Aug 20, 2026
ChengDa Pharmaceuticals Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 458.3 | 406.37 | 333.13 | 414.3 | 411.46 | 415.73 |
Revenue Growth | 48.54% | 21.99% | -19.59% | 0.69% | -1.03% | 11.44% |
Gross Profit Gross Profit Growth | 142.93 | 137.12 | 125.8 | 175.37 | 182.92 | 200.02 |
Operating Income Operating Income Growth | -8.26 | -19.13 | -69 | 57.68 | 70.27 | 112.08 |
Net Income Net Income Growth | -3.52 | -11.93 | -28.1 | 90.98 | 106.48 | 100.44 |
Earnings Per Share EPS Growth | -0.02 | -0.08 | -0.18 | 0.59 | 0.70 | 0.87 |
EPS Growth | - | - | - | -16.33% | -18.80% | -17.11% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
China China Growth | 260.24 | 223.5 | 264.94 | 205.85 | 194.96 |
Foreign Foreign Growth | 146.13 | 109.63 | 149.37 | 205.61 | 220.76 |
Total Total Growth | 406.37 | 333.13 | 414.3 | 411.46 | 415.73 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 964.14 | 995.88 | 1,136 | 1,364 | 1,381 | 18.49 |
Total Debt Total Debt Growth | 59.11 | 59.11 | 80.12 | - | - | 69.06 |
Net Cash (Debt) Net Cash Growth | 905.02 | 936.77 | 1,056 | 1,364 | 1,381 | -50.56 |
Net Cash Growth | -9.72% | -11.29% | -22.58% | -1.26% | - | - |
Net Cash Per Share Net Cash Per Share Growth | 5.98 | 6.18 | 6.95 | 8.82 | 9.12 | -0.44 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 45.57 | 34.02 | 28.65 | 192.07 | 47.67 | 83.14 |
Capital Expenditures CapEx Growth | -58.19 | -69.02 | -286.36 | -224.67 | -205.69 | -138.7 |
Free Cash Flow Free Cash Flow Growth | -12.63 | -35 | -257.72 | -32.6 | -158.03 | -55.56 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 31.19% | 33.74% | 37.76% | 42.33% | 44.45% | 48.11% |
Operating Margin | -1.80% | -4.71% | -20.71% | 13.92% | 17.08% | 26.96% |
Pretax Margin | -0.52% | -3.26% | -8.16% | 25.16% | 29.19% | 27.73% |
Profit Margin | -0.77% | -2.94% | -8.44% | 21.96% | 25.88% | 24.16% |
FCF Margin | -2.76% | -8.61% | -77.36% | -7.87% | -38.41% | -13.36% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.200 | 0.200 | 0.200 | 0.200 | 0.188 | 0.281 |
Dividend Per Share Growth | 0% | 0% | 0% | 6.67% | -33.34% | - |
Dividend Yield | 0.54% | 0.49% | 1.00% | 0.81% | 0.61% | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | 43.24 | 46.13 | - |
PS Ratio | 12.81 | 15.17 | 9.18 | 9.50 | 11.94 | - |